Seropositive Rheumatoid Arthritis Drug Market Overview
MRFR (Market Research Future) expects the seropositive rheumatoid arthritis drug market 2020 to procure an approximate CAGR of 4.0% between 2017and 2023 (analysis period). We will provide COVID-19 impact analysis with the report, along with all the extensive key developments in the market post the coronavirus disease outbreak.
Request Free Sample Copy Available Here!! https://www.marketresearchfuture.com/sample_request/5572
Key Boosters and Deterrents
Rheumatoid arthritis impacts close to 1% of the worldwide population, and its symptoms include swelling, stiffness and joint pain. These symptoms are also accompanied by inability to do regular activities and chronic pain. Over an extended period, the disorder can proceed to affect the person’s mobility and cause permanent damage to the joint. Without treatment, RA could altogether leave the person’s mobility impaired and also heighten the need for joint replacement. The increased burden of the disease, the growing presence of biosimilars and biologics along with extensive regulatory guidelines are projected to benefit the global market in the following years.
The market for seropositive rheumatoid arthritis drug has been gaining momentum on the back of the surging number of smokers, increasing spending on healthcare and the expanding female and obese population. Rigorous research and development of products pipelines and the continuous emergence of new novel products could be the key market trends in the future. A few other trends boosting the market growth include the rising introduction of novel biologics and the escalation in promising clinical pipeline candidates. Also, mounting awareness about the drugs that are safer for consumption can also work in the favor of the global market.
Some of the treatment options for RA available in the market are generic pharmaceuticals that include corticosteroids and NSAIDs coupled with novel biologics like IL-6 antagonists and JAK inhibitors. These find significant demand in developed nations owing to their considerable effectiveness. Product development and launches including Adalimumab and Infliximab biosimilars are expected to induce major growth in the seropositive rheumatoid arthritis drug market. For instance, in May 2020, Teva Pharmaceuticals USA, Inc. banded together with Celltrion Healthcare, Co., Ltd to launch TRUXIMA/rituximab-abbs injection in the US, for the treatment of rheumatoid arthritis. The primary target will be the adult patients that live with moderate to severe RA, and have not responded to one or higher number of tumor necrosis factor antagonist therapies.
Seropositive Rheumatoid Arthritis Drug Market Segmental Analysis
Seropositive rheumatoid arthritis drug industry has been dissected in terms of drug class, drug, treatment and diagnosis, route of administration, application, and end user.
The drug classes discussed in the report are Steroids, Disease-modifying anti-rheumatic drug type (DMARDs), biologic agents and Non-steroidal anti-inflammatory drug type (NSAID).
Drug-wise, the market segments could be Enbrel (etanercept), Humira (adalimumab), Rituxan (rituximab), Remicade (infliximab), Orencia (abatacept), Actemra (tocilizumab), and more.
The various treatment lines available in the market are tendon repair, synovectomy, total joint replacement and joint fusion.
With respect to diagnosis, the global market has been considered for CCP, C -reactive protein (CRP) Test, Synovial Fluid Analysis and ESR (Erythrocyte Sedimentation Rate) Test.
Routes of administration for seropositive rheumatoid arthritis drugs are intravenous, subcutaneous, oral, and others.
Primary applications are scientific research, medicine, and others.
The top end users in the industry include ambulatory surgical centers, diagnostic centers, hospital, and others.
Seropositive Rheumatoid Arthritis Drug Market Regional Study
The regional study of the seropositive rheumatoid arthritis drug industry covers Europe, the Americas, MEA/Middle East and Africa and APAC/Asia Pacific.
With the biggest share in the global market, America has taken the lead backed by factors including the expanding population of individuals affected by autoimmune diseases. Seropositive rheumatoid arthritis is quite common in the US, affecting close to 1.3 million people. Increased efforts by the pharmaceutical vendors in terms of product development for treating rheumatoid arthritis happen to be another key reason behind the market’s strong performance.
APAC is a region that brimming with a host of lucrative opportunities and is emerging at the fastest rate in the global market. Soaring number of global investors are taking interest in the region, in the wake of fast economic growth across countries such as Japan, India, Taiwan and China. Apart from this, governments are taking up initiatives to accelerate the awareness level among people about rheumatoid arthritis, which is perceived to be a significant growth inducer in the regional market. The rapid advancements in the field of novel biologics and biosimilars in the region are also viewed as key opportunities by the leading companies and could ensure further market expansion in subsequent years.
Seropositive Rheumatoid Arthritis Drug Market Top Market Contenders
Top contenders in the worldwide market include Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Vertex Pharmaceuticals Incorporated (U.S), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Johnson & Johnson Limited (U.S.), Abbott Laboratories (U.S.), GlaxoSmithKline Inc. (U.S.), Merck and Co. Inc. (U.S.), Cadila Healthcare Ltd. (India), Sanofi-Aventis (France), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen (U.S.), Novartis AG (Switzerland), AstraZeneca (U.K), and more.
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/seropositive-rheumatoid-arthritis-drug-market-5572
Related Report Available In Healthcare Industry
Population Health Management Market Information: Component (Hardware and Others), Solution (Data Integration & Management, Analytics, and Others), Delivery Mode (On-Premise and Others), End-User (Healthcare Providers, Others) –Global Forecast Till 2023
Ayurveda Market Information by application (medicinal, personal care), by disease pattern (respiratory system, nervous systems, gastrointestinal tract, cardiovascular system, infectious diseases, skeletal system, skin and hair), by source (vegetable, animal and mineral), by form (herbal, herbomineral, mineral), by end-users (academia and research, hospitals and clinics), by distribution – Global Forecast to 2023
Connected Healthcare Market: Information by Type (M-Health Services, (Wearable Devices, Blood Pressure Monitor and Big Data) M-Health Devices and E-Prescription), by Application (Monitoring, Diagnosis & Treatment, Education & Awareness, Healthcare Management and Wellness & Prevention) and Region (North America, Europe, Asia-Pacific and Middle East & Africa) – Forecast till 2025 About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312
NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.